Laserscope's GreenLight PV(R) System the Focus of 11 Presentations at Recent European Association of Urology Annual Meeting
2006年5月16日 - 9:00PM
PRニュース・ワイアー (英語)
SAN JOSE, Calif., May 16 /PRNewswire-FirstCall/ -- Laserscope
(NASDAQ:LSCP), a leader in the development and commercialization of
minimally-invasive medical devices, including medical lasers and
advanced fiber-optic delivery devices, today announced that its
GreenLight PV(R) laser system was the focus of 11 separate
presentations delivered by leading physicians to attendees of the
European Association of Urology (EAU) Annual Meeting held in Paris,
France last month. Leading hospitals from six countries including
Switzerland, Turkey, South Korea, the United Kingdom and Norway
presented their results. Groups from Switzerland and Korea reported
results of two benchmark trials comparing Photoselective
Vaporization of the Prostate (PVP) utilizing the GreenLight PV
laser system with Transurethral Resection of the Prostate (TURP).
The results from both concluded that the modalities provide
comparable functional outcomes, but that PVP provides superior
intraoperative safety and shorter hospital stays and
catheterization times. Other key findings from various countries
were that the costs for both modalities were comparable and that
PVP patients experienced low re-treatment rates. Investigators from
Switzerland reported a low re-treatment rate of 3.5% in a large
cohort of 285 PVP patients followed for over 24 months.
Investigators from Turkey reported no impairment of erectile
function of PVP. Studies from the United Kingdom, Turkey and
Switzerland showed results of PVP treatment in elderly patients,
patients in retention and those with large glands that mimic
published studies from the United States. Additionally, PVP under
local anesthesia with IV sedation was demonstrated to be safe and
effective in a cohort of 83 patients treated by a group from
Trondheim, Norway. Patients were discharged in eight hours on
average after the procedure with a mean catheterization time of
only two hours. "We were delighted to see our GreenLight PV system
as a focal point of this important urology forum in Europe. As
international acceptance and adoption of the (PVP) procedure
continues to grow steadily, the favorable data presented at the EAU
clearly demonstrates the potential for PVP to become the worldwide
standard of care for BPH (Benign Prostatic Hyperplasia, or
non-cancerous, enlarged prostate)," said Eric Reuter, President and
Chief Executive Officer of Laserscope. "Results of the anesthesia
study from Norway add a new perspective to PVP in an outpatient
setting." About the European Association of Urology The European
Association of Urology (EAU) is the largest scientific urological
organization in Europe. The EAU connects 16,000 urologists,
urologists-in-training and urological scientists in Europe and
worldwide. http://www.uroweb.org/ About Laserscope Founded in 1984,
Laserscope (NASDAQ:LSCP) is a pioneer in the development and
commercialization of minimally-invasive medical devices, including
medical lasers and advanced fiber-optic delivery devices for
physician offices, outpatient surgical centers and hospitals. The
Company's GreenLight PV(R) laser systems are used for the
Photoselective Vaporization of the Prostate (PVP) procedure in the
treatment of benign prostatic hyperplasia. The PVP procedure is
gaining acceptance as an alternative to Trans Urethral Resection of
the Prostate (TURP) for treatment of the enlarged prostate. For
more information about Laserscope, please visit
http://www.laserscope.com/. Safe Harbor Statement This press
release contains forward-looking information within the meaning of
Section 21E of the Securities Exchange Act of 1934, and is subject
to the safe harbor created by this section. These forward-looking
statements include the market opportunity for our surgical products
and their competitiveness in that market, worldwide adoption rates
of the PVP procedure using the GreenLight PV(R) laser system, our
ability to compete with similar product offerings and other
therapies for the treatment of BPH and market penetration
opportunities in international markets. These statements are
subject to a number of risks and uncertainties, including:
uncertainties regarding introduction of new technologies
competitive to Laserscope's products and the degree to which our
current and new products are accepted by customers, which could
affect the level of demand for our products; uncertainties
regarding the impact that competitive products and therapies as
well as private and public payer reimbursement levels for the PVP
procedure could have on the competitiveness of our current pricing
programs, which could adversely impact our financial results; risk
of reductions in government and private insurance reimbursement of
hospitals and physicians for health care costs, which may
negatively impact hospitals and physicians decisions to purchase
our products reducing adoption rates and sales growth; risks that
we may be unable to protect adequately the integrity, safety and
proper use of our disposable fiber optic delivery device with the
GreenLight PV(R) laser system, which could result in negative
patient outcomes and reduce our disposable delivery device
recurring revenue stream; risks that patents and licenses that we
hold may be challenged, invalidated or circumvented or that we may
become the subject of intellectual property litigation;
uncertainties regarding our ability to compete with companies that
have significantly greater financial, technical, research and
development, manufacturing and marketing resources than we have;
and uncertainties that new products will receive regulatory
approval in applicable jurisdictions. The matters discussed in this
press release also involve risks and uncertainties described from
time to time in Laserscope's filings with the Securities and
Exchange Commission. In particular, see the Risk Factors described
in Laserscope's most recent Report on Form 10-Q. Copies of
Laserscope's public disclosure filings with the SEC, including the
most recent Annual Report on Form 10-K and the most recent forms
10-Q are available upon request from its Investor Relations
Department at its website at http://www.laserscope.com/ and at the
SEC's website: http://www.sec.gov/. Laserscope assumes no
obligation to update the forward-looking information contained in
this press release. DATASOURCE: Laserscope CONTACT: Eric Reuter,
President & CEO, or Derek Bertocci, CFO, both of Laserscope,
+1-408-943-0636; or Investor/Analysts, Tricia Ross,
+1-617-520-7064, or General Inquiries, Moira Conlon,
+1-310-854-8311, both of Financial Relations Board, for Laserscope
Web site: http://www.uroweb.org/ Web site:
http://www.laserscope.com/
Copyright
Laserscope (NASDAQ:LSCP)
過去 株価チャート
から 9 2024 まで 10 2024
Laserscope (NASDAQ:LSCP)
過去 株価チャート
から 10 2023 まで 10 2024